Get started
SRPT LongSarepta Therapeutics Focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases investorrelations.sarepta.com Major leader in treatment - Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) - Explore perespective produts in Gene therapy and editing Fundamentals: - Growing Revenue and EPS - Trading at historical low PE - Far below market consensus $148 Technicals - Near low 200VWAP extension 30% discount
NASDAQ:SRPTLong
by fondOrange28771
Marker Therapeuticss a high-risk, high-reward investmeMarker Therapeutics (NASDAQ: MRKR) is a biotech company focused on multi-antigen T cell (MAR-T) therapies targeting hematological malignancies and solid tumors. The company recently published its FY2024 results, highlighting promising clinical progress but also significant financial challenges. As of the end of 2024, Marker reported $19.2 million in cash, with an annual operational burn rate of approximately $10.9 million. This cash position suggests a financial runway extending through the first quarter of 2026, assuming no additional financing. However, the company issued a "going concern warning" in its financial statements, flagging the risk of cash depletion within 12–15 months​. On the clinical side, preliminary data from the APOLLO trial for its lead candidate MT-601 in patients with relapsed/refractory lymphoma post-CAR-T therapy are encouraging, with an objective response rate (ORR) of 78% and a complete response (CR) rate of 44%. Meanwhile, the pancreatic cancer program for MT-601, backed by over $11.5 million in non-dilutive NIH and CPRIT grants, is set to enter clinical development in the second half of 2025. An additional milestone was the approval of "neldaleucel" as the official generic name for MT-601, marking regulatory progress. Nevertheless, Marker faces substantial structural risks. These include its heavy reliance on the success of MT-601, the urgent need for new funding within the next year, intense competition in the cellular therapy field, and complete reliance on third-party manufacturers after selling its own production facilities. From a valuation perspective, two scenarios can be considered. In a conservative scenario, assuming only partial success in the lymphoma program and dilutive fundraising, the estimated enterprise value would be around $24–26 million, corresponding to a theoretical share price of approximately $2.40–2.60. In an optimistic scenario, assuming full clinical success across both lymphoma and pancreatic programs and effective fundraising, the market valuation could rise to $75–95 million, implying a theoretical share price of about $8.80. However, adjusting for early-stage biotech risk (estimated success probability of 10–15%), the realistic fair value ranges between $0.90 and $1.30 per share​. In conclusion, Marker Therapeutics represents a high-risk, high-reward investment opportunity, suitable only for highly specialized biotech investors. The coming months will be critical, with particular focus on updated APOLLO trial data and the company's ability to secure additional funding or strategic partnerships.
NASDAQ:MRKR
by andreapriolo10
LGVN Bullish opportunity Longeveron Inc. (LGVN) offers a strong bullish opportunity as it nears a potential breakout from its prevailing downtrend. The stock has been consolidating with increasing volume and tightening price ranges, indicating accumulating buyer interest. A decisive break above the critical resistance level of $1.92, coinciding with the downtrend's upper trendline, could trigger a bullish reversal, propelling LGVN toward an initial target of $2.25, with further upside potential to $2.60. Traders should watch for strong volume confirmation and stay mindful of broader market conditions to manage risks effectively. Not advise for buying or selling, just I like what I do :)
NASDAQ:LGVNLong
by NEVERMINDS1
$EBAY $80 EOYA non factor amongst tariff rhetoric. I think the idea of US consumers (even internationally) buying and reselling has never been higher. I think a lot of consumers will start to look for used goods more than ever. I'm eyeing $70 calls for earnings this upcoming week (first week of May 2025) and if it has any pull back I will load the boat for $80 call leaps. I like the structure it's held at this $55-$65 range. I expect new highs on this name maybe earnings can give it a jolt. All the lines you see are 20, 50, 200 SMA and EMA. I could be wrong on earnings as this name tends to dip from earnings even posting beats but that's the gamble of earnings but LONG TERM this name is a good buy. Charts are Monthly and Daily. WSL.
NASDAQ:EBAYLong
by wallstreetloser001
IQiyi (IQ) - updating the Chart and story-trading during crisisNASDAQ:IQ some notes on the iqiyi chart. 1: fundamentals: the stock is expected to earn 20 cents this year and eventually grow to 50 cents per share eps, earnings power and earnings growth is very attractive at current prices. 2:Technicals: 2.00 level is significant for may and june options cycle. could we be in a major wedge at the 3 to 1.50 levels, marking a coiling up area. we took out the all time low of oct 2022 and make a new low around 1.50. , could this become a major accumulation zone during the trump/china tarriff crisis? 3.Sentiment: chinese stocks are very hated and under owned, there are many chinese stocks trading at or below tangible book value, news is very dark seeming for trade in china, with many chinese manufacturers shutting down due to lack of usa product demand with tarriff uncertainty. Bullish I love moments like this. they are not easy to trade and invest in. But they are real time history happening before our eyes. Sand through your hands. Remember these times.
NASDAQ:IQLong
by ValuePig
$RDAR - Massive Weekly Slingshot, 1000x Potential RunnerWeekend scan continues to find the best candidates into this 8 year cycle - OTC:RDAR , wow is all I can say, this has massive potential once it breaks into sub territory with volume. The hype is in the AI buzz and the constant awareness for their product in the media. Raadr Inc. (OTC: RDAR), also known as Telvantis Inc., is a U.S.-based technology company specializing in AI-driven software solutions aimed at combating cyberbullying and online harassment. The company offers tools for real-time monitoring of social media and digital platforms, targeting parents, schools, and law enforcement agencies. If we learned anything about share structures with bloated OS/AS, it won't mean a damn thing once this sling gets going to the upside - remember how HMBL/ENZC/SNPW, had massive floats and still ran from trips to dollars... I got that itchin' feelin' again, taking a starter Monday and will add on momentum into the sling.
OTC:RDARLong
by ilovestocks85
NVDIA Death Cross Quant Perspectives (Light Case Study)NASDAQ: Nvidia (NVDA ) has recently experienced an uptrend after a death cross formed consisting of the 65 and 200 EMAs on the 1 Day chart. If we analyze back on Nvidia starting in 1999 , we can count a total of 10 death crosses that have occurred, and 9 have been immediately followed by downtrends. Although a single death cross did not have an immediate downtrend, shortly after this event (approx. 282 days) another death cross formed and price then fell roughly twice as it historically has , almost appearing to make up for the missed signal. From a quantitative perspective: If we calculate the raw historical success rate using: Raw Success Rate = 9/10 = 90 With this calculation the observed success of 65/200 EMA death crosses correlating to an immediate downtrend is 90% In order to avoid overconfidence we can apply Laplace smoothing using: Smoothed Probability = 9+1/10+2 = 10/12 or 0.8333 With this calculation the observed success of 65/200 EMA death crosses correlating to an immediate downtrend is 83% Given the results of the data I personally feel that there is a Very High (83%) chance this death cross that recently formed on the 1 Day chart (around 04/16/2025) will immediately lead to a downtrend. And a Low (17%) chance it does not. Furthermore these results support a technical analysis hypothesis that I formed prior. Many different systemic factors can contribute to the market movement, but mathematics sometimes leave subtle clues. Will the market become bearish? Or will Nvidia gain renewed bullish interest? Disclaimer: Not Financial Advice.
NASDAQ:NVDAShort
by TRADEABLESKUNK
5